Document is current
Any future updates will be listed below
-
Authors
Paik, Paul K. https://orcid.org/0000-0002-9464-3984
Luo, Jia https://orcid.org/0000-0003-3606-827X
Ai, Ni
Kim, Rachel
Ahn, Linda
Biswas, Anup
Coker, Courtney https://orcid.org/0000-0002-8779-133X
Ma, Wanchao
Wong, Phillip https://orcid.org/0000-0002-6360-849X
Buonocore, Darren J.
Lai, W. Victoria
Chaft, Jamie E.
Acharyya, Swarnali
Massagué, Joan
Kris, Mark G.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA-129243, CA-008748, CA-009207, TR-00457, CA172697, CA129243)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
A Society of MSKCC (Memorial Sloan Kettering Cancer Center) grant UCB, Inc also sponsored this study.
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Conquer Cancer Foundation
U.S. Department of Defense (W81XWH-17-1-0441)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Herbert Irving Scholar Award
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 27 July 2021
Accepted: 29 September 2022
First Online: 15 October 2022
Competing interests
: P.K.P. receives compensation for consulting or advisory board participation from Bicara Therapeutics, Inc., EMD Serono, Inc., Takeda Pharmaceuticals, Xencor, Inc, and Mirati; receives honoraria for participation in CME educational programs from PeerVoice, ACE Oncology, Research to Practice, Clinical Care Options, Physicians’ Education Resource, Axis Medical Education, and Medscape. J.L. has received honoraria from Targeted Oncology and Physicians’ Education Resource. L.A. is a member of the specialty oncology board for ABIM and receives honorarium for this work. P.W. has received consultation fees from Leap Therapeutics. W.V.L. receives institutional research funding from Daiichi Sankyo, Amgen, and Abbvie; has been a compensated consultant for PharmaMar, G1 Therapeutics, AstraZeneca, Jazz Pharmaceuticals. J.E.C. has served as a consultant for Astra Zeneca, Bristol-Myers Squib, Genentech, Merck, Flame Biosciences, Novartis, Regeneron-Sanofi, Guardant Health, and Janssen; has received research funding to her institution from Astra Zeneca, Bristol-Myers Squib, Genentech, and Merck. M.G.K. received personal fees from Novartis, Sanofi, AstraZeneca, Pfizer, Janssen, and Daiichi-Sankyo; received honoraria for participation in educational programs from WebMD, OncLive, Physicians Education Resources, Intellisphere, Continuing Education Alliance, i3 Health, PHSA Corporation, Nexus Health Media, Ideology Health, and AstraZeneca; received travel support from Pfizer and Daiichi-Sankyo; received editorial support from Hoffman La-Roche. M.G.K. is an employee of Memorial Sloan Kettering. Memorial Sloan Kettering has received research funding from The National Cancer Institute (USA), The Lung Cancer Research Foundation and Genentech Roche for research conducted by M.G.K. MSK has licensed testing for EGFR T790M to MolecularMD. The remaining authors declare no competing interests.
